

CORRECTION

Open Access



Correction to: A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial

Timothy Devos^{1,2*†}, Tatjana Geukens^{1,2†}, Alexander Schauwvlieghe^{3†}, Kevin K. Ariën⁴, Cyril Barbezange⁵, Myriam Cleeren¹, Veerle Compennolle⁶, Nicolas Dauby⁷, Daniël Desmecht⁸, David Grimaldi⁹, Bart N. Lambrecht³, Anne Luyten¹⁰, Piet Maes¹¹, Michel Moutschen⁸, Marta Romano⁵, Lucie Seyler¹², Michel Toungouz Nevegnisky¹³, Katleen Vandenberghe¹⁰, Johan van Griensven⁴, Geert Verbeke¹⁴, Erika Vlieghe¹⁵, Jean Cyr Yombi¹⁶, Laurens Liesenborghs¹¹, Peter Verhamme¹ and Geert Meyfroidt¹

Correction to: *Trials* 21, 981 (2020)
<https://doi.org/10.1186/s13063-020-04876-0>

Following publication of the original article [1], we were notified of a typing mistake in one of the author names.

Originally published name: Alexander Schauwvlieghe.

Corrected name: Alexander Schauwvlieghe.

The original article has been corrected.

Author details

¹University Hospitals Leuven (UZ Leuven), Leuven, Belgium. ²Catholic University of Leuven (KU Leuven), Leuven, Belgium. ³Universitair Ziekenhuis Gent, Ghent, Belgium. ⁴Instituut voor Tropische Geneeskunde, Antwerp,

Belgium. ⁵Sciensano, Elsenne, Belgium. ⁶Rode Kruis Vlaanderen, Mechelen, Belgium. ⁷Universite Libre de Bruxelles Institut d'Immunologie Medicale, Bruxelles, Belgium. ⁸Universite de Liege, Liege, Belgium. ⁹Universite Libre de Bruxelles, Bruxelles, Belgium. ¹⁰Leuven Coordinating Centre, Leuven, Belgium. ¹¹Katholieke Universiteit Leuven Rega Institute for Medical Research, Leuven, Belgium. ¹²Universitair Ziekenhuis Brussel, Bruxelles, Belgium. ¹³Croix Rouge de Belgique, Bruxelles, Belgium. ¹⁴Interuniversity Institute for Biostatistics and statistical Bioinformatics, Leuven, Belgium. ¹⁵Universitair Ziekenhuis Antwerpen, Antwerpen, Belgium. ¹⁶Cliniques Universitaires Saint-Luc, Sint-Lambrechts-Woluwe, Belgium.

Published online: 14 December 2020

Reference

1. Devos, et al. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. *Trials*. 2020;21:981. <https://doi.org/10.1186/s13063-020-04876-0>.

The original article can be found online at <https://doi.org/10.1186/s13063-020-04876-0>.

* Correspondence: timothy.devos@uzleuven.be

[†]Timothy Devos, Tatjana Geukens and Alexander Schauwvlieghe are co-first authors.

¹University Hospitals Leuven (UZ Leuven), Leuven, Belgium

²Catholic University of Leuven (KU Leuven), Leuven, Belgium

Full list of author information is available at the end of the article



© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.